JPWO2019106361A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019106361A5 JPWO2019106361A5 JP2020526986A JP2020526986A JPWO2019106361A5 JP WO2019106361 A5 JPWO2019106361 A5 JP WO2019106361A5 JP 2020526986 A JP2020526986 A JP 2020526986A JP 2020526986 A JP2020526986 A JP 2020526986A JP WO2019106361 A5 JPWO2019106361 A5 JP WO2019106361A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- compound
- formula
- solid dosage
- oral solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008184 oral solid dosage form Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000007787 solid Substances 0.000 claims 18
- 239000008187 granular material Substances 0.000 claims 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims 9
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 150000002632 lipids Chemical class 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 6
- 230000001404 mediated Effects 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 6
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 5
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 230000002792 vascular Effects 0.000 claims 5
- 210000002381 Plasma Anatomy 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 3
- 206010030113 Oedema Diseases 0.000 claims 3
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical class OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- -1 dexstrad Substances 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 239000008273 gelatin Substances 0.000 claims 3
- 229920000159 gelatin Polymers 0.000 claims 3
- 235000019322 gelatine Nutrition 0.000 claims 3
- 235000011852 gelatine desserts Nutrition 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- 230000002207 retinal Effects 0.000 claims 3
- 235000020945 retinal Nutrition 0.000 claims 3
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 claims 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 102000003827 Plasma kallikrein Human genes 0.000 claims 2
- 108090000113 Plasma kallikrein Proteins 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims 1
- 239000005995 Aluminium silicate Substances 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- 239000004135 Bone phosphate Substances 0.000 claims 1
- 229960003563 Calcium Carbonate Drugs 0.000 claims 1
- 229940078495 Calcium phosphate dibasic Drugs 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 206010018987 Haemorrhage Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 210000004165 Myocardium Anatomy 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010029149 Nephropathy Diseases 0.000 claims 1
- 206010029151 Nephropathy Diseases 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229940069328 Povidone Drugs 0.000 claims 1
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 206010040070 Septic shock Diseases 0.000 claims 1
- 229940005550 Sodium alginate Drugs 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 229940046009 Vitamin E Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- XYFGTTCGHCGTDZ-ZRVLSRDKSA-N [(2R,3S,4S,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl hexadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 XYFGTTCGHCGTDZ-ZRVLSRDKSA-N 0.000 claims 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2S,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 claims 1
- ZZXIXQRNGZFIQT-JSJITEFISA-N [(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (Z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O ZZXIXQRNGZFIQT-JSJITEFISA-N 0.000 claims 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 230000001058 adult Effects 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 235000012211 aluminium silicate Nutrition 0.000 claims 1
- 229940116224 behenate Drugs 0.000 claims 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 claims 1
- 230000000740 bleeding Effects 0.000 claims 1
- 231100000319 bleeding Toxicity 0.000 claims 1
- 201000004569 blindness Diseases 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 229960001714 calcium phosphate Drugs 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 235000011132 calcium sulphate Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000271 cardiovascular Effects 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-M erucate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC([O-])=O DPUOLQHDNGRHBS-KTKRTIGZSA-M 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 125000005456 glyceride group Chemical class 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 125000001095 phosphatidyl group Chemical class 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 150000003019 phosphosphingolipids Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000019814 powdered cellulose Nutrition 0.000 claims 1
- 229920003124 powdered cellulose Polymers 0.000 claims 1
- 230000000241 respiratory Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592242P | 2017-11-29 | 2017-11-29 | |
US62/592,242 | 2017-11-29 | ||
GB1721515.3 | 2017-12-21 | ||
GBGB1721515.3A GB201721515D0 (en) | 2017-12-21 | 2017-12-21 | Dosage forms comprising a plasma kallikrein inhibtor |
PCT/GB2018/053443 WO2019106361A1 (en) | 2017-11-29 | 2018-11-28 | Dosage forms comprising a plasma kallikrein inhibitor |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2021504312A JP2021504312A (ja) | 2021-02-15 |
JP2021504312A5 JP2021504312A5 (ro) | 2022-01-04 |
JPWO2019106361A5 true JPWO2019106361A5 (ro) | 2022-03-07 |
JP7078722B2 JP7078722B2 (ja) | 2022-05-31 |
Family
ID=72846742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020526986A Active JP7078722B2 (ja) | 2017-11-29 | 2018-11-28 | 血漿カリクレイン阻害剤を含む剤形 |
Country Status (17)
Country | Link |
---|---|
US (1) | US11234939B2 (ro) |
JP (1) | JP7078722B2 (ro) |
CY (1) | CY1125227T1 (ro) |
DK (1) | DK3716952T3 (ro) |
ES (1) | ES2909893T3 (ro) |
HR (1) | HRP20220367T1 (ro) |
HU (1) | HUE057912T2 (ro) |
IL (2) | IL312036A (ro) |
LT (1) | LT3716952T (ro) |
MD (1) | MD3716952T2 (ro) |
MX (1) | MX2020005168A (ro) |
PL (1) | PL3716952T3 (ro) |
PT (1) | PT3716952T (ro) |
RS (1) | RS63069B1 (ro) |
RU (1) | RU2020121151A (ro) |
SI (1) | SI3716952T1 (ro) |
ZA (1) | ZA202003899B (ro) |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
MXPA01010292A (es) | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
DE60218511T2 (de) | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
AR039329A1 (es) | 2002-04-26 | 2005-02-16 | Lilly Co Eli | Derivados de triazol, antagonistas de receptor de taquicinina |
EP1426364A1 (en) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Imidazole-derivatives as factor Xa inhibitors |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
JP2007527363A (ja) | 2003-02-03 | 2007-09-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | バニロイドvr1受容体のモジュレーターであるキノリン誘導アミド |
EP3168304A1 (en) | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
AU2005280738B2 (en) | 2004-09-03 | 2010-11-25 | Yuhan Corporation | Pyrrolo(3,2-c)pyridine derivatives and processes for the preparation thereof |
US8841259B2 (en) | 2005-02-24 | 2014-09-23 | Joslin Diabetes Center | Compositions and methods for treating vascular permeability |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
EA200800321A1 (ru) | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
ES2385505T3 (es) | 2006-07-06 | 2012-07-25 | Glaxo Group Limited | N-fenilmetil-5-oxo-prolina-2-amidas sustituidas como antagonistas del receptor P2X7 y métodos de uso |
CA2658523C (en) * | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
JP5295976B2 (ja) | 2006-12-29 | 2013-09-18 | アボット ゲーエムベーハー ウント カンパニー カーゲー | カルボキサミド化合物およびカルパイン阻害剤としてのこれらの使用 |
WO2008091692A2 (en) | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
US20080221094A1 (en) | 2007-03-07 | 2008-09-11 | Harald Bluhm | Metalloprotease inhibitors containing a squaramide moiety |
NZ579892A (en) | 2007-03-30 | 2012-03-30 | Sanofi Aventis | Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors |
AU2008234855B2 (en) | 2007-04-03 | 2011-01-20 | Glaxo Group Limited | Imidazolidine carboxamide derivatives as P2X7 modulators |
US8324263B2 (en) | 2007-07-26 | 2012-12-04 | Syngenta Crop Protection, Llc | Microbiocidally active carboxamides |
CA2696429A1 (en) | 2007-08-22 | 2009-02-26 | Allergan, Inc. | Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
WO2009083553A1 (en) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
US8658685B2 (en) | 2008-01-31 | 2014-02-25 | Activesite Pharmaceuticals, Inc. | Methods for treatment of kallikrein-related disorders |
WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
BRPI0915473A2 (pt) | 2008-07-08 | 2015-11-10 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica, e, uso de um composto |
US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
EP2512466A4 (en) | 2009-12-18 | 2013-07-03 | Activesite Pharmaceuticals Inc | PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN |
JP2011157349A (ja) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 |
CN102858744B (zh) | 2010-01-28 | 2015-03-04 | 医药公司(莱比锡)有限公司 | 胰蛋白酶样丝氨酸蛋白酶抑制剂及其制备方法和用途 |
JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
EP2458315B1 (de) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung |
WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
WO2012174362A1 (en) | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
WO2013048982A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
US9249096B2 (en) | 2011-09-27 | 2016-02-02 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
AU2013216721B2 (en) | 2012-02-10 | 2017-09-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013130603A1 (en) | 2012-02-27 | 2013-09-06 | Board Of Regents, The University Of Texas System | Ganglioside gd2 as a marker and target on cancer stem cells |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
CA2894642A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
RU2019101889A (ru) | 2013-03-15 | 2019-03-28 | Версеон Корпорейшн | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз |
RU2712621C2 (ru) | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
WO2015022546A1 (en) | 2013-08-14 | 2015-02-19 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
MX2016008688A (es) | 2013-12-30 | 2017-01-12 | Lifesci Pharmaceuticals Inc | Compuestos terapéuticos inhibidores. |
PL3113772T3 (pl) | 2014-03-07 | 2021-04-06 | Biocryst Pharmaceuticals, Inc. | Pirazole podstawiane trifluorometylem jako inhibitory ludzkiej kalikreiny osoczowej |
WO2015171526A2 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Tricyclic pyrazolopyridine compounds |
WO2015171527A1 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
MX2017000450A (es) | 2014-07-16 | 2017-08-16 | Lifesci Pharmaceuticals Inc | Compuestos terapeuticos inhibidores. |
ES2954451T3 (es) | 2014-08-22 | 2023-11-22 | Biocryst Pharm Inc | Composiciones y usos de derivados de amidina |
CA2960790A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
US10532995B2 (en) | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
CA2991171A1 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
US20190263818A1 (en) | 2015-07-01 | 2019-08-29 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
JP6917988B2 (ja) | 2015-10-27 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
WO2017072021A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
RS60600B1 (sr) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
WO2019106359A1 (en) | 2017-11-29 | 2019-06-06 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
-
2018
- 2018-11-28 RU RU2020121151A patent/RU2020121151A/ru unknown
- 2018-11-28 IL IL312036A patent/IL312036A/en unknown
- 2018-11-28 ES ES18815293T patent/ES2909893T3/es active Active
- 2018-11-28 LT LTEPPCT/GB2018/053443T patent/LT3716952T/lt unknown
- 2018-11-28 SI SI201830613T patent/SI3716952T1/sl unknown
- 2018-11-28 MX MX2020005168A patent/MX2020005168A/es unknown
- 2018-11-28 HR HRP20220367TT patent/HRP20220367T1/hr unknown
- 2018-11-28 HU HUE18815293A patent/HUE057912T2/hu unknown
- 2018-11-28 RS RS20220166A patent/RS63069B1/sr unknown
- 2018-11-28 IL IL274557A patent/IL274557B1/en unknown
- 2018-11-28 MD MDE20201002T patent/MD3716952T2/ro unknown
- 2018-11-28 PL PL18815293T patent/PL3716952T3/pl unknown
- 2018-11-28 JP JP2020526986A patent/JP7078722B2/ja active Active
- 2018-11-28 DK DK18815293.8T patent/DK3716952T3/da active
- 2018-11-28 US US16/767,803 patent/US11234939B2/en active Active
- 2018-11-28 PT PT188152938T patent/PT3716952T/pt unknown
-
2020
- 2020-06-26 ZA ZA2020/03899A patent/ZA202003899B/en unknown
-
2022
- 2022-03-16 CY CY20221100207T patent/CY1125227T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101699912B1 (ko) | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 | |
JP5794650B2 (ja) | 難溶性薬物の溶解性改善製剤 | |
KR20160045728A (ko) | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 | |
KR20210016436A (ko) | 글루코키나제 활성화제 및 ppar 수용체 활성화제를 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도 | |
KR20050053690A (ko) | 텔미사탄을 포함하는 고형 약제학적 제형 | |
WO2014120982A1 (en) | Solid dispersion formulation of an antiviral compound | |
HUE029853T2 (en) | Pharmaceutical formulations containing 1- (beta-D-Glucopyranosyl) -2-thienylmethylbenzene derivatives as SGLT inhibitors | |
US11819577B2 (en) | Fixed dose pharmaceutical composition of valsartan and sacubitril | |
JP5479909B2 (ja) | 新規製剤 | |
KR101907881B1 (ko) | 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형 | |
US20070134315A1 (en) | Orally administrable extended release pellet and tablet formulations of a highly water soluble compound | |
JP2006501274A (ja) | オキシカルバゼピンおよびその誘導体の改良放出製剤 | |
JP2009529061A (ja) | 錠剤製剤およびプロセス | |
KR101585280B1 (ko) | 고형 의약 제제 | |
CN114096530B (zh) | 一种复合物的药物组合物及其制备方法 | |
JP2019512537A (ja) | ダパグリフロジンの医薬組成物 | |
WO2021074808A1 (en) | Pharmaceutical composition comprising sacubitril and valsartan and process for preparation thereof | |
JP6716464B2 (ja) | 酢酸亜鉛水和物錠及びその製造方法 | |
EP3886817A1 (en) | Pharmaceutical composition comprising ramipril and indapamide | |
JPWO2019106361A5 (ro) | ||
JP2021504312A5 (ro) | ||
US20200222395A1 (en) | Pharmaceutical compositions of lurasidone | |
WO2020101596A2 (en) | A capsule composition comprising sunitinib | |
WO2020055359A2 (en) | Oral dosage form of sorafenib tosylate | |
KR20210024593A (ko) | 도파민-β-히드록실라제 억제제를 포함하는 제제 및 이의 제조 방법 |